Nuvectra Corporation

Nuvectra — Investor Presentation (March 2016)

27 slides from Nuvectra's investor presentation, Mar 30, 2016

  1. Slide 1: Investor Presentation: New directions in neurostimulation

    NUVECTRA’ Investor Presentation New directions in neurostimulation March 2016

  2. Slide 2: Legal Disclaimer

    Legal Disclaimer Basis of Presentation The information included inthis presentation regarding QiG Group, LLC. which will comer into Nuvectra Corporation prior to the completion of the spin-of (Nuvectra’, the “Company”, ‘we" or “our assumes the completion of the spin-off of Nuvectra by Greatbatch, In

  3. Slide 3: Transaction Overview

    Transaction Overview Company Nuvectra Corporati Ticker Symbol (When-Issued) NVTR.V Ticker Symbol (Regular Way) NVTR When-lssued Trading Expected to Begin March 3% Record Date March 7 Spin-Off Effective Date/ Distribution Date March 14%" First Regular Way Day of Trading March 14! Distribution Ratio 1

  4. Slide 4: Nuvectra Positioned for Success

    Nuvectra Positioned for Success Large & Growing Target Markets $2.6B") *Spinal Cord Stimulation (SCS) + Sacral Nerve Stimulation (SNS) +Deep Brain Stimulation (DBS) NUVECTRA Platform Technology + Expansive IP portfolio *Access to multiple markets & indications *Partnering opportunities + Powerful IP

  5. Slide 5: Neurostimulation Targeted Market Opportunity

    Neurostimulation Targeted Market Opportunity $2.6B Target Market in 2014 7.5% CAGR through 2018 SNS Market?) DBS Market’) a 8 96% Chronic Pain Bladder & Bowel Control Movement Disorders $1.6B $520M $540M 6% CAGR 9.5% CAGR 10% CAGR sig $20 s6aq $750 ss 8 690 lil [ T Hn | ill “2014 2015 2016 2017 2018

  6. Slide 6: Platform Designed for Multiple Indications

    Platform Designed for Multiple Indications Expansive Proprietary IP P Issued 407 Issued 49 = a Physician & Patient Programmers Proprietary Processors NUVECTRA

  7. Slide 7: Building a Neurostimulation Company

    Building a Neurostimulation Company 2009 2010 2011 | 2012 2013 2014 201 2016 scs Product Planning (Market Research, Giinician Partners, Competitive Landscape) Product Design & Development Regulatory Submissions fegultory Approves & Conmertaizaton EI ce tiarc approval toragowtarecenved une 2014 HS ro

  8. Slide 8: SCS — Our First Opportunity

    SCS — Our First Opportunity Chronic Pain'".2) 1.5B WW suffer from chronic pain 100M Americans suffer from severe and chronic pain $300B annual healthcare spend in the US Chronic pain sufferers are also affected with depression, sleep depravation and overall reduced quality of life Spinal Cord Stimul

  9. Slide 9: SCS Large & Growing Market

    SCS Large & Growing Market Strong Market Growth(") $1.56B SCS Market in 2014!) US: $1,130M (72% / WW) a a am m Z a = ous: $429M (28% / WW) 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 MM Medtronic Mi StJude f™™ Boston Scientific ll Nevro Treating back & leg pain NUVECTRA (1strerazeintmainsamain

  10. Slide 10: World Renowned SCS Physician Advisors

    World Renowned SCS Physician Advisors ai a ay = y Giancarlo Barolat, MD | Chief Medical Advisor + Professor of Neurosurgery, Thomas Jefferson University, Philadelphia, PA (1985-2005) + Director, Barolat Neuroscience Center at Presbyterian St. Luke's Hospital, Denver, CO (2005-present) + Director of

  11. Slide 11: Experienced Leadership Team

    Experienced Leadership Team Scott Drees | President, CEO, & Director QIG Group Founding Partner + Founding Division President, Advanced Neuromodulation Systems Inc. (ANSI) * Prior experience: St. Jude Medical, Boston Scientific, Johnson & Johnson + 35 yrs. implantable medical devices experience; 20

  12. Slide 12: Understanding Market Needs

    Understanding Market Needs N 1 (@ +Ease of implant *Pain reduction *Cost effective products +Clinical performance +Discreet device versus alternative therapies +Lead options +Easy to use +Efficacy +Reliability & longevity *Comfortable & convenient us Seinhies cit + Significant reduction in implified

  13. Slide 13: Algovita SCS System

    Algovita SCS System Powerful Versatile Usable NUVECTRA

  14. Slide 14: Powerful IPG Therapy Delivery

    Powerful IPG Therapy Delivery + 24 channels + Large battery capacity + Broad parametric ranges + Bi-directional recharge + MICS wireless telemetry + Embedded program memory Proprietary Stimulation & Power Processors Configuration Be 48 oe # of Channels, 16 32 16 # of Power Sources 24 4 4 2 4 Volume

  15. Slide 15: A New Generation of Lead Design

    A New Generation of Lead Design Electrode 42-£lectrode Market Opportunities Algovita , + Increase spinal coverage + Lead elongation + Reduce lead migration (13%) *) + Reduce lead breakage (9%) (1 COIL DESIGN UNCONSTRAINED INDEPENDENT COIL IN COIL DESIGN COIL STRUCTURE STRAIGHT WIRE STRAIGHT WIRE DUA

  16. Slide 16: A New Generation of Lead Design

    A New Generation of Lead Design Algovita | © | = Competitive Leads + Larger volume er + Challenging placement ee + Lack of steering i + Not stretchable Epidural pace Thin Profile Surgical Lead Design NUVECTRA

  17. Slide 17: Simplifying Programming Complexity

    Simplifying Programming Complexity Patient 7 + Wireless telemetry + Colored touchscreens + Highly intuitive + Patient interactive programming + Discreet & portable patient control Clinician Competitive Devices Patient Controllers PatientIPG Rechargers NUVECTRA

  18. Slide 18: Algorithm for SCS Success

    Algorithm for SCS Success A Place leads B. Confirm lead position C. Close 2. Post-operative: Patient Interactive Programming & Optimization @) Hi ts A. Patient identifies 8, Optimize stimulation C. Provide activity optimal contacts program options 3. Daily Usage: Patient in Control of Their Therapy

  19. Slide 19: U.S. Commercialization

    U.S. Commercialization Hire Proven Team of + Build world class team Sales Talent + Foster high achieving culture Sales management, direct reps, * Eoous.on'SCS market share sales agents, clinical specialists + Initiate clinical studies + Establish technology leadership Rep Productivity Ramp Capture M

  20. Slide 20: SNS — Our Second Opportunity

    SNS — Our Second Opportunity Indications System + Urinary Incontinence se * Overactive Bladder (OAB): Cepemer Urgency Incontinence & Urgency Frequency isa, Urinary Retention + Fecal Incontinence soe acer Market Landscape") Market Opportunity $520M (2014) 9.5% CAGR Market Share $750 630 $690 50 $570

  21. Slide 21: DBS - Strategic Partnership

    DBS - Strategic Partnership Partnership Overview + Development agreement through 2017 + Nuvectra expected to license platform of IPG and programmers to Aleva for royalties + Aleva provides MEMS technology with directSTIM directional DBS lead + Field of use: DBS for Parkinson's Disease (PD) and Essen

  22. Slide 22: NeuroNexus

    4} NeuroNexus Designs, develops and manufactures leading edge neuroscience technology and devices for clinical research markets Neurostim Penetrating Deep Brain Surface Giede, Chemical Nerve palvery Sensing MRI Optogenetics Smartbox™ High-performance 256 channel recording system Provides early visib

  23. Slide 23: Nuvectra Spin Off

    Nuvectra Spin Off & Greatbatch ‘The Spin’ 2009-2015 2016 Cash Contribution= $75M Funding Greatbatch Funded R&D + Credit Facility = $452 Phase Design & Development Commercialization MARKET RESEARCH REGULATORY: SYSTEM VERIFICATION CLINICAL & VALIDATION SALES & MARKETING COMPANY FORMATION SCONCE: STRAT

  24. Slide 24: Nuvectra Manufacturing

    Nuvectra Manufacturing Designed by Nuvectra Long-term supply agreement with Greatbatch NUVECTRA See Nuvectra's Registration Statement on Form 10 for other key agreements

  25. Slide 25: Financial Overview

    Financial Overview Results of Operations Year Ended (Sin Millions, except percentages) Sales Costof sales Gross profit Gross margin Operating expenses: Selling, general and administrative Research, development, and engineering, net Other operating expenses (income), net Total operating expenses Loss

  26. Slide 26: Pro Forma Balance Sheet

    Pro Forma Balance Sheet Balance Sheet Pro-forma ($ in Million: Actual Post Spin-Off Cash and cash equivalents $0.2 $75.2 Total assets $45.4 $120.4 Total liabilities $7.6 $7.6 Accumulated loss $(125.1) $0 Total equity $37.8 $112.8 NUVECTRA

  27. Slide 27: Nuvectra Positioned for Success

    Nuvectra Positioned for Success Large & Growing Target Markets $2.6B") *Spinal Cord Stimulation (SCS) + Sacral Nerve Stimulation (SNS) +Deep Brain Stimulation (DBS) NUVECTRA Platform Technology + Expansive IP portfolio *Access to multiple markets & indications *Partnering opportunities + Powerful IP

Nuvectra — Investor Presentation (March 2016) on 6ix